top of page

Publications

​​​​

Von Hippel-Lindau and Pseudohypoxia

  • Halperin R, Horwitz R, Schwarz Y, Tirosh A. Pseudohypoxia caused by germline genetic alterations in the VHL gene is associated with increased diabetes and cardiovascular risk: a UK biobank study. Cardiovasc Diabetol. 2025 Jun 4;24(1):239. doi: 10.1186/s12933-025-02799-1.

  • Kahan Yossef Y, Sela Peremen L, Telerman A, Goldinger G, Malitsky S, Itkin M, Halperin R, Peshes Yaloz N, Tirosh A. Single-cell transcriptomics and metabolomic analysis reveal adenosine-derived metabolites over-representation in pseudohypoxic neuroendocrine tumours. Clin Transl Med. 2025 Feb;15(2):e70159. doi: 10.1002/ctm2.70159.

  • Halperin R, Tirosh A. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Cancers (Basel). 2023 Mar 13;15(6):1739. doi: 10.3390/cancers15061739.

  • Halperin R, Arnon L, Eden-Friedman Y, Tirosh A. Unique Characteristics of Patients with Von Hippel-Lindau Disease Defined by Various Diagnostic Criteria. Cancers (Basel). 2023 Mar 8;15(6):1657. doi: 10.3390/cancers15061657.

  • Arnon L, Halperin R, Tirosh A. Impact of Pancreatic Neuroendocrine Tumor on Mortality in Patients With von Hippel-Lindau Disease. Endocr Pract. 2021 Oct;27(10):1040-1045. doi: 10.1016/j.eprac.2021.03.005. Epub 2021 Mar 15.

  • Tirosh A, Journy N, Folio LR, Lee C, Leite C, Yao J, Kovacs W, Linehan WM, Malayeri A, Kebebew E, Berrington de González A. Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. Radiology. 2019 Jan;290(1):116-124. doi: 10.1148/radiol.2018180687. Epub 2018 Oct 9.

  • Tirosh A, El Lakis M, Green P, Nockel P, Patel D, Nilubol N, Gara SK, Keutgen XM, Linehan WM, Kebebew E. In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1631-1638. doi: 10.1210/jc.2017-02434.

  • Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. JAMA Oncol. 2018 Jan 1;4(1):124-126. doi: 10.1001/jamaoncol.2017.3428.

 

Pheochromocytoma/paraganglioma and Neuroendocrine Tumors

  • Sela Peremen L, Telerman A, Kahan Yossef Y, Peshes Yaloz N, Tirosh A. Netrin-DCC inhibition suppresses neuroendocrine neoplasm growth in vivo. Endocr Relat Cancer. 2025 Nov 5;32(11):e250226. doi: 10.1530/ERC-25-0226. 

  • Halperin R, Tirosh A. Mid-Treatment Response to 177-Lutetium Dotatate Predicts Overall Outcome in Patients With Advanced Neuroendocrine Tumors. JCO Oncol Pract. 2024 Oct;20(10):1401-1409. doi: 10.1200/OP.23.00789. Epub 2024 Jun 27.

  • Kaplinsky A, Halperin R, Shlomai G, Tirosh A. Role of epigenetic regulation on catecholamine synthesis in pheochromocytoma and paraganglioma. Cancer. 2024 Oct 1;130(19):3289-3296. doi: 10.1002/cncr.35426. Epub 2024 Jun 14.

  • Halperin R, Urban D, Tirosh A. A Case of Metastatic Thymoma Responsive to Treatment With 177 Lu-DOTATATE. Clin Nucl Med. 2023 Apr 1;48(4):e190-e192. doi: 10.1097/RLU.0000000000004553. Epub 2023 Jan 14.

  • Halperin R, Ahron-Hananel G, Badarna M, Greidinger D, Uri I, Percik R, Tirosh A. Plasma Hemoglobin and Red Blood Cell Mass Levels as Dynamic Prognostic Markers for Progression and Survival in Pancreatic Neuroendocrine Tumors. Horm Metab Res. 2021 Dec;53(12):810-817. doi: 10.1055/a-1672-4653. Epub 2021 Dec 10.

  • Peltz-Sinvani N, Percik R, Uri I, Kfir SK, Tirosh A, Tirosh A. Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas. Endocrine. 2021 Sep;73(3):745-751. doi: 10.1007/s12020-021-02740-y. Epub 2021 May 12.

  • Badarna M, Percik R, Aharon-Hananel G, Uri I, Tirosh A. Anatomic site as prognostic marker of pancreatic neuroendocrine tumors: a cohort study. Eur J Endocrinol. 2019 Sep;181(3):325-330. doi: 10.1530/EJE-19-0332.

  • Nockel P, Tirosh A, El Lakis M, Gaitanidis A, Merkel R, Patel D, Nilubol N, Sadowski SM, Cochran C, Gorden P, Kebebew E. Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. Endocrine. 2018 Sep;61(3):422-427. doi: 10.1007/s12020-018-1633-1. Epub 2018 Jun 19.

  • Laitman Y, Tzur S, Attai R, Tirosh A, Friedman E. Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma. Genet Res (Camb). 2020 May 1;102:e3. doi: 10.1017/S0016672320000038.

 

Multiple endocrine neoplasia 1 and 4

  • Halperin R, Tirosh A. Progress report on multiple endocrine neoplasia type 1 Fam Cancer. 2025 Jan 18;24(1):15. doi: 10.1007/s10689-025-00440-4.

  • Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M, Telerman A, Friedman E, Bernstein-Molho R, Tirosh A. Germline CDKN1B variant type and site are associated with phenotype in MEN4 Endocr Relat Cancer. 2022 Dec 12;30(1):e220174. doi: 10.1530/ERC-22-0174. Print 2023 Jan 1.

  • Kfir SK, Halperin R, Percik R, Uri I, Halpern N, Shlomai G, Laish I, Tirosh A, Tirosh A. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors Horm Metab Res. 2021 May;53(5):319-325. doi: 10.1055/a-1464-1276. Epub 2021 Apr 20.

  • Lee ME, Ortega-Sustache YM, Agarwal SK, Tepede A, Welch J, Mandl A, Bansal R, Tirosh A, Piaggi P, Cochran C, Simonds WF, Weinstein LS, Blau JE. Patients With MEN1 Are at an Increased Risk for Venous Thromboembolism J Clin Endocrinol Metab. 2021 Jan 23;106(2):e460-e468. doi: 10.1210/clinem/dgaa501.

 

Pituitary and other

  • Haver N, Halperin R, Bar-On Y, Tripto-Shkolnik L, Badarne M, Tirosh A. Serum phosphate levels at diagnosis predict long-term risk for hypopituitarism in patients with acromegaly. Hormones (Athens). 2024 Dec;23(4):727-734. doi: 10.1007/s42000-024-00578-3. Epub 2024 Jul 6.

  • Greidinger D, Halperin R, Zemet R, Maixner N, Tirosh A. Somatic USP8 alteration affects the immune landscape of corticotroph pituitary adenomas- a pilot study. Hormones (Athens). 2024 Dec;23(4):717-725. doi: 10.1007/s42000-024-00569-4. Epub 2024 May 31.

  • Assaf D, Gutman Y, … , Tirosh A. Utilization of machine-learning models to accurately predict the risk for critical COVID-19. Intern Emerg Med. 2020 Nov;15(8):1435-1443. doi: 10.1007/s11739-020-02475-0. Epub 2020 Aug 18.

  • Aharon-Hananel G, Percik R, Badarna M, Uri I, Tirosh A. Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. Endocrine. 2019 Aug;65(2):393-398. doi: 10.1007/s12020-019-01996-9. Epub 2019 Jul 2.

 

Collaborations

  • Somech E, Halder D, Spitzer A, Barbolin C, Tyler M, Halperin R, Biton M, Tirosh A*, Tirosh I*. Subtypes and proliferation patterns of small intestine neuroendocrine tumors revealed by single-cell RNA sequencing. Elife. 2025 Jul 23;13:RP101153. doi: 10.7554/eLife.101153.

  • Franke M, Daly AF, Palmeira L, Tirosh A, … , Beckers A, Stratakis CA, Trivellin G. Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism. Am J Hum Genet. 2022 Apr 7;109(4):553-570. doi: 10.1016/j.ajhg.2022.02.002. Epub 2022 Feb 23.

  • Trivellin G, Tirosh A, Hernández-Ramírez LC, Gupta T, Tsai-Morris CH, Faucz FR, Burgess HA, Feldman B, Stratakis CA. The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish. Mol Cell Endocrinol. 2021 Jan 15;520:111091. doi: 10.1016/j.mce.2020.111091. Epub 2020 Nov 26.

 

Guidelines and Statements

  • Brandi ML, Pieterman CRC, English KA, Lines KE, Shariq OA, Marini F, Cuny T, Lewis MA, Stratakis CA, Perrier ND, Waguespack SG, Castinetti F, Valk GD, Thakker RV; Delphi Expert Panel. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice Lancet Diabetes Endocrinol. 2025 Aug;13(8):699-721. doi: 10.1016/S2213-8587(25)00119-6. Epub 2025 Jun 13.

  • Daniels AB, Tirosh A, Huntoon K, Mehta GU, Spiess PE, Friedman DL, Waguespack SG, Kilkelly JE, Rednam S, Pruthi S, Jonasch EA, Baum L, Chahoud J; International VHL Surveillance Guidelines Consortium. Guidelines for surveillance of patients with von Hippel-Lindau disease: Consensus statement of the International VHL Surveillance Guidelines Consortium and VHL Alliance Cancer. 2023 Oct 1;129(19):2927-2940. doi: 10.1002/cncr.34896. Epub 2023 Jun 19.

  • Laks S, van Leeuwaarde R, Patel D, Keutgen XM, Hammel P, Nilubol N, Links TP, Halfdanarson TR, Daniels AB, Tirosh A; Pancreatic Manifestations Recommendations Development Subcommittee of the VHL Alliance. Management recommendations for pancreatic manifestations of von Hippel-Lindau disease Cancer. 2022 Feb 1;128(3):435-446. doi: 10.1002/cncr.33978. Epub 2021 Nov 4.

  • Ear PH, Marinoni I, Dayton T, Guenter R, Quelle DE, Battistella A, Buishand FO, Chittaranjan S, Nancy Du YC, Marques I, Pellegata NS, Sadowski SM, Tirosh A, April-Monn S, Aurilia C, Jaskula-Sztul R, Baena Moreno MJ, Donati S, English KA, Hernandez Llorens MA, Hodgetts H, Marini F, Martins M, Palmini G, Soldevilla B, Schrader J, Thakker RV, Lines KE. NET Models Meeting 2024 white paper: the current state of neuroendocrine tumour research models and our future aspirations Endocr Oncol. 2024 Dec 19;4(1):e240055. doi: 10.1530/EO-24-0055. eCollection 2024 Jan 1.

​

bottom of page